We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 510

Bristol-Myers Squibb obtains order of prohibition against Mylan regarding efavirenz

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • October 5 2012

On September 27, 2012, Justice Barnes of the Federal Court granted Bristol-Myers Squibb ("BMS") an Order prohibiting the Minister of Health from issuing a notice of compliance ("NOC") to Mylan Pharmaceuticals ULC for a generic efavirenz product (BMS's SUSTIVA) until the expiry of Patent No. 2,101,572 (’572), but not Patent No. 2,279,198 (’198

Pfizer v Ratiopharm, appeal of decision on invalidity, Amlodipine Besylate, July 29, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • August 26 2010

In the Federal Court, Pfizer's patent for amlodipine besylate was held invalid on numerous grounds, including obviousness

Court affirms utility of Gleevec patent

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 20 2013

"Sound prediction's introduction into Canadian law was not, as I understand it, to give a crushing hammer to those who challenge patents." Snider J

Eli Lilly Canada Inc. v. Apotex Inc (2010 FCA 240)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 27 2010

This was an appeal of the decision of Madame Justice Gauthier (in the Federal Court) who had found that although Lilly met its burden to prove that Apotex infringed eight Lilly process patents related to the manufacture of the antibiotic cefaclor for material imported before June 3, 1998, Lilly failed to do so for the cefaclor imported into Canada after June 3, 1998

Working group recommends that PMPRB adopts DIP methodology permanently

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • August 1 2012

In May 2012 the Patented Medicine Prices Review Board (PMPRB) released a report in which the DIP working group recommended that the PMPRB adopt the DIP methodology on a permanent basis

Supreme Court of Canada: VIAGRA patent "void" for insufficient disclosure

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • November 8 2012

The Supreme Court of Canada today released the hotly anticipated decision in Teva Canada Limited v Pfizer Canada Inc, 2012 SCC 60 (sildenafil, VIAGRA

Federal Court upholds validity of patent for escitalopram (CIPRALEX)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 19 2013

Apotex Inc. (“Apotex”) brought an action for impeachment seeking a declaration that Lundbeck’s Canadian Patent No. 1,339,452 (the “’452 Patent”) is

Pfizer v. Novopharm, appeal of decision of prothonotary to deny Novopharm’s motion for confidentiality in PMNOC Regulations case, pregabalin, June 21, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 16 2010

Novopharm served a NOA on Pfizer which it had unilaterally designated confidential

Patent for esomeprazole tablets found not to be obvious

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 29 2013

AstraZeneca Canada Inc. and AstraZeneca AB (“AstraZeneca”) brought an application pursuant to section 6 of the Patented Medicines (Notice of

US Supreme Court releases Myriad, isolated DNA unpatentable what it means for Canada

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada, USA
  • -
  • June 13 2013

The Supreme Court of the United States today issued its opinion in Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al., 569 U